Evidence map›Paper›PMID 35980610›Full record

ArticleJAMA ophthalmology2022

Association of Ultra-Widefield Fluorescein Angiography-Identified Retinal Nonperfusion and the Risk of Diabetic Retinopathy Worsening Over Time.

Paolo S Silva, Dennis M Marcus, Danni Liu, Lloyd Paul Aiello, Andrew Antoszyk, Michael Elman, Scott Friedman, Adam R Glassman, Joseph M Googe, Lee Merrill Jampol and 6 more

Erratum issuedOpen access · greenAbstract readComment
In one paragraph

Article in JAMA ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 65 citations in OpenAlex.

  1. MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2026
    Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Case series: The role of retinal ischemia in the pathogenesis and clinical manifestation of diabetic retinopathy.Optometry and vision science : official publication of the American Academy of Optometry · 2026
    Article
  7. Article
  8. Predictors of vision-threatening proliferative diabetic retinopathy in the fellow eye after unilateral vitrectomy: a clinical and imaging-based study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Observational
  15. Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Posterior Retinal Ischemia Correlates With Vision in Patients With Diabetes.Investigative ophthalmology & visual science · 2025
    Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 1 country.

Paolo S SilvaJoslin Diabetes Center, Beetham Eye Institute, Boston, Massachusetts.
Dennis M MarcusSoutheast Retina Center, Augusta, Georgia.
Danni LiuJaeb Center for Health Research, Tampa, Florida.
Lloyd Paul AielloJoslin Diabetes Center, Beetham Eye Institute, Boston, Massachusetts.
Andrew AntoszykCharlotte Eye Ear Nose and Throat Associates, Charlotte, North Carolina.
Michael ElmanElman Retina Group, Baltimore, Maryland.
Scott FriedmanFlorida Retina Consultants, Lakeland.
Adam R GlassmanJaeb Center for Health Research, Tampa, Florida.
Joseph M GoogeSoutheastern Retina Associates, Knoxville, Tennessee.
Lee Merrill JampolFeinberg School of Medicine, Northwestern University, Chicago, Illinois.
Daniel F MartinCole Eye Institute, Cleveland Clinic, Cleveland, Ohio.
Michele MeliaJaeb Center for Health Research, Tampa, Florida.
Carin M PrestonJaeb Center for Health Research, Tampa, Florida.
Charles C WykoffRetina Consultants of Texas, Houston.
Jennifer K SunJoslin Diabetes Center, Beetham Eye Institute, Boston, Massachusetts.
DRCR Retina Network
Jaeb Center for Health Research · USJoslin Diabetes Center · USAugusta University · USCalifornia Retina Consultants · USCharlotte Eye Ear Nose & Throat Associates · USCleveland Clinic · USElman Retina Group · USNorthwestern University · USRetina Consultants of Texas · USSoutheastern Retina Associates · US

Funding

DRCR Retina NetworkUG1EY014231 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI Adam R Glassman, DANIEL F MARTIN · 2019 to 2026
$75.4M
SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
NEI NIH HHS UG1 EY014231NIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

Importance: Presence of predominantly peripheral diabetic retinopathy (DR) lesions on ultra-widefield fluorescein angiography (UWF-FA) was associated with greater risk of DR worsening or treatment over 4 years. Whether baseline retinal nonperfusion assessment is additionally predictive of DR disease worsening is unclear. Objective: To assess whether the extent and location of retinal nonperfusion identified on UWF-FA are associated with worsening in Diabetic Retinopathy Severity Scale (DRSS) score or DR treatment over time. Design, Setting, and Participants: This cohort study was a prospective, multicenter, longitudinal observational study with data for 508 eyes with nonproliferative DR and gradable nonperfusion on UWF-FA at baseline. All images were graded at a centralized reading center; 200° ultra-widefield (UWF) color images were graded for DR at baseline and annually for 4 years. Baseline 200° UWF-FA images were graded for nonperfused area, nonperfusion index (NPI), and presence of predominantly peripheral lesions on UWF-FA (FA PPL). Interventions: Treatment of DR or diabetic macular edema was at investigator discretion. Main Outcomes and Measures: Association of baseline UWF-FA nonperfusion extent with disease worsening, defined as either 2 or more steps of DRSS worsening within Early Treatment Diabetic Retinopathy Study fields on UWF-color images or receipt of DR treatment. Results: After adjusting for baseline DRSS, the risk of disease worsening over 4 years was higher in eyes with greater overall NPI (hazard ratio [HR] for 0.1-unit increase, 1.11; 95% CI, 1.02-1.21; P = .02) and NPI within the posterior pole (HR for 0.1-unit increase, 1.35; 95% CI, 1.17-1.56; P < .001) and midperiphery (HR for 0.1-unit increase, 1.08; 95% CI, 1.00-1.16; P = .04). In a multivariable analysis adjusting for baseline DRSS score and baseline systemic risk factors, greater NPI (HR, 1.11; 95% CI, 1.02-1.22; P = .02) and presence of FA PPL (HR, 1.89; 95% CI, 1.35-2.65; P < .001) remained associated with disease worsening. Conclusions and Relevance: This 4-year longitudinal study has demonstrated that both greater baseline retinal nonperfusion and FA PPL on UWF-FA are associated with higher risk of disease worsening, even after adjusting for baseline DRSS score and known systemic risk. These associations between disease worsening and retinal nonperfusion and FA PPL support the increased use of UWF-FA to complement color fundus photography in future efforts for DR prognosis, clinical care, and research.

Indexed as

Diabetes MellitusDiabetic RetinopathyMacular EdemaCohort StudiesFluorescein AngiographyHumansLongitudinal StudiesPhotographyProspective StudiesRetinal Vessels

Identifiers

PMID35980610
PMCPMC9389436
OpenAlexW4294308720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.